---
title: "LifeSci Capital Sticks to Their Buy Rating for Inventiva (IVA)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280881352.md"
description: "LifeSci Capital analyst Rami Katkhuda has reaffirmed a Buy rating for Inventiva (IVA) with a price target of $14.00. The analyst consensus for Inventiva is a Strong Buy, with an average price target of $15.50. Katkhuda, who specializes in the Healthcare sector, has an average return of 32.0% and a success rate of 53.85% on his stock recommendations."
datetime: "2026-03-28T14:38:22.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280881352.md)
  - [en](https://longbridge.com/en/news/280881352.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280881352.md)
---

# LifeSci Capital Sticks to Their Buy Rating for Inventiva (IVA)

LifeSci Capital analyst Rami Katkhuda maintained a Buy rating on Inventiva today and set a price target of $14.00.

### Claim 30% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Katkhuda covers the Healthcare sector, focusing on stocks such as Amylyx Pharmaceuticals Inc, Disc Medicine, and Viridian Therapeutics. According to TipRanks, Katkhuda has an average return of 32.0% and a 53.85% success rate on recommended stocks.

Currently, the analyst consensus on Inventiva is a Strong Buy with an average price target of $15.50.

### Related Stocks

- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [IVA.US](https://longbridge.com/en/quote/IVA.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)

## Related News & Research

- [Assessing Inventiva (ENXTPA:IVA) Valuation After Recent Share Price Volatility](https://longbridge.com/en/news/286962960.md)
- [LifeSci Capital Sticks to Their Buy Rating for Tenax Therapeutics (TENX)](https://longbridge.com/en/news/286648286.md)
- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [Shah Capital Management Will Vote ‘No' Across Five Proposals On Novavax's June 18 Ballot - SEC Filing](https://longbridge.com/en/news/286565204.md)